Diligence memo · auto-generated · as of July 2, 2026
Singular Bio, Inc.
Singular Bio, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Singular Bio, Inc. operates in Biotech / Pharma, based in SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Singular Bio, Inc. has raised $6.6M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.6M on 2019-01-31.
Most recent recorded round closed around 2019-01-31.
Valuation (modeled)modeled
Provath models Singular Bio, Inc. at approximately $220M (range $7.4M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.32× the median modeled value of Series A Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era. Within the normal band (132% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7.4 yr ago; this sector typically re-raises about every 15 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 55% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 80% of those peers.
Closest niche peers: Advanced Bio Development, Inc., Generian Pharmaceuticals, Inc., Teiko Bio, Inc., Genomic Prediction, Inc., Abreos Biosciences, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.